Behavioral effects of NBQX, a competitive antagonist of the AMPA receptors

Pharmacology Biochemistry and Behavior

Volumn 59, Issue 4, 1998, Pages 1087-1092

  Filliat, Pierre ^a   Pernot Marino, Irmine ^a   Baubichon, Dominique ^a   Lallement, Guy ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

AMPA receptors; Morris water maze; Motor behavior; NBQX; Open field; Rats; Spatial memory

Indexed keywords

6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; BRAIN ISCHEMIA; BRAIN PROTECTION; CONTROLLED STUDY; DRUG EFFECT; LOCOMOTION; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; SPATIAL MEMORY;

ANIMALS; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MAZE LEARNING; MEMORY; MOTOR ACTIVITY; QUINOXALINES; RATS; RATS, WISTAR; RECEPTORS, AMPA;

ANIMALIA; ATAXIA;

EID: 0032052684     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(97)00518-2     Document Type: Article

References (40)

1. Arai A., Kessler M., Xiao P., Ambros-Ingerson J., Rogers G., Lynch G. A. Centrally active drug that modulates AMPA receptor gated currents. Brain Res. 638:1994;343-346.
2. Balchen T., Diemer N. H. The AMPA antagonist, NBQX, protects against ischemia-induced loss of cerebral Purkinje cells. Neuroreport. 3:1992;785-788.
3. Berg M., Bruhn T., Johansen F. F., Diemer N. H. Kainic acid-induced seizures and brain damage in the rat. Different effects of NMDA- and AMPA receptor antagonists Pharmacol. Toxicol. 73:1993;262-268.
4. Browne S. E., McCulloch J. AMPA receptor antagonists and local cerebral glucose utilization in the rat. Brain Res. 641:1994;10-20.
5. Buchan, A. M.; Lesiuk, H.; Barnes, K. A.; Li, H.; Huang, Z. G.; Smith, K. E.; Xue, D.: AMPA antagonists: do they hold more promise for clinical stroke trials than NMDA antagonists? Stroke 24:I148-I152; 1993.
6. Buchan A. M., Li H., Cho S., Pulsinelli W. A. Blockade of the AMPA receptor prevents CA1 hippocampal injury following severe but transient forebrain ischemia in adult rats. Neurosci. Lett. 132:1991;255-258.
7. Buchan A. M., Xue D., Huang Z.-G., Smith K. H., Lesiuk H. Delayed AMPA receptor blockade reduces cerebral infarction induced by focal ischemia. Neuroreport; 2:1991;473-476.
8. Chapman A. G., Meldrum B. S. Excitatory amino acid antagonists and epilepsy. Excitatory Amino Acids. 21:1993;106-110.
9. Chapman A. G., Smith S. E., Meldrum B. S. The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466, in mice. Epilepsy Res. 9:1991;92-96.
10. Danys W., Essmann U., Bresink I., Wilke R. Glutamate antagonists have different effects on spontaneous locomotor activity in rats. Pharmacol. Biochem. Behav. 48:1994;111-118.
11. Dürmüller N., Craggs M., Meldrum B. S. The effect of the non-NMDA receptor antagonists GYKI 52466 and NBQX and the non competitive NMDA receptor antagonist D-CPPene on the development of amygdala kindling and on amygdala-kindled seizures. Epilepsy Res. 17:1994;167-174.
12. Flood J. F., Baker M. L., Davis J. L. Modulation of memory processing by glutamic acid receptor agonists and antagonists. Brain Res. 521:1990;197-202.
13. Gill R., Nordholm L., Lodge D. The neuroprotective actions of 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) in a rat focal ischemia model. Brain Res. 580:1992;35-43.
14. Goldstein J. M., Litwin L. C. NBQX is a selective non-NMDA receptor antagonist in rat hippocampal slice. Mol. Chem. Neuropathol. 18:1993;145-152.
15. Granger R., Staubli U., Davis M., Perez Y., Nilsson L., Rogers G. A., Lynch G. A drug that facilitates glutamatergic transmission reduces exploratory activity and improves performance in a learning-dependent task. Synapse. 15:1993;326-329.
16. Klockgether T., Turski L., Honoré T., Zhang Z., Gash D. M., Kurlan R., Greenamyre J. T. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann. Neurol. 30:1991;717-723.
17. Lallement G., Pernot-Marino I., Foquin-Tarricone A., Baubichon D., Piras A., Blanchet G., Carpentier P. Antiepileptic effects of NBQX angainst soman-induced seizures. Neuroreport. 5:1994;425-428.
18. Lallement G., Pernot-Marino I., Foquin-Tarricone A., Baubichon D., Piras A., Blanchet G., Carpentier P. Coadministration of atropine, NBQX and TCP against soman-induced seizures. Neuroreport. 5:1994;1113-1117.
19. LePeillet E., Arvin B., Moncada C., Meldrum B. S. The non-NMDA antagonists, NBQX and GYKI 52466, protect against cortical and striatal cell loss following transient global ischemia in the rat. Brain Res. 571:1994;115-120.
20. Li H., Buchan A. M. Treatment with an AMPA antagonist 12 hours following severe normothermic forebrain ischemia prevents CA1 neuronal injury. Cereb. Blood Flow Metab. 13:1993;933-939.
21. Löscher W., Hönack D. Anticonvulsant and behavioral effects of two novel competitive N-methyl-D-aspartic acid receptor antagonists, CGP 37849 and CGP 39551, in the kindking model of epilepsy. Comparison with MK-801 and carbamazepine. J. Pharmacol. Exp. Ther. 256:1991;432-440.
22. Löscher W., Hönack D. Responses to NMDA receptor antagonists altered by epileptogenesis. Trends Pharmacol. Sci. 12:1991;52.
23. Löscher W., Hönack D. Effects of the non-NMDA antagonists NBQX and the 2,3-benzodiazepine GYKI 52466 on different seizure types in mice. Comparison with diazepam and interactions with flumazenil Br. J. Pharmacol. 113:1994;1349-1357.
24. Löscher W., Hönack D. Over-additive anticonvulsant effect of memantine and NBQX in kindled rats. Eur. J. Pharmacol. 259:1994;R3-R5.
25. Löscher W., Rundfeldt C., Hönack D. Low doses of NMDA receptor antagonists synergistically increase the anticonvulsant effect of the AMPA receptor antagonist NBQX in the kindling model of epilepsy. Eur. J. Neurosci. 5:1993;1545-1550.
26. Maldonado-Irizarry C. S., Kelley A. E. Excitatory amino acid receptors within nucleus accumbens subregions differentially mediate spatial learning in the rat. Behav. Pharmacol. 6:1995;527-539.
27. Parada J., Czuczwar S. J., Turski W. A. NBQX does not affect learning and memory tasks in mice. A comparison with D-CPPene and ifenprodil Cogn. Brain Res. 1:1992;67-71.
28. Parsons C. G., Gruner R., Rozental J. Comparative patch clamp studies on the kinetics and selectivity of glutamate receptor antagonism by 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F) quinoxaline (NBQX) and 1-(4-Amino-phenyl)-4 methyl-7,8-methyl-endioxyl-5H-2,3-benzodiazepine (GYKI 52466). Neuropharmacology. 33:1994;589-604.
29. Sheardown M. J., Nielsen E. O., Hansen A. J., Jacobsen P., Honoré T. 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline. A neuroprotectant for cerebral ischemia Science. 247:1990;571-574.
30. Sheardown M. J., Sudzak P. D., Nordholm L. AMPA but not NMDA, receptor antagonism is neuroprotective in gerbil global ischaemia, even when delayed 24 h. Eur. J. Pharmacol. 236:1993;347-353.
31. Staubli U., Rogers G., Lynch G. Facilitation of glutamate receptors enhances memory. Proc. Natl. Acad. Sci. USA. 91:1994;777-781.
32. Steele R. J., Stewart M. G. Involvement of AMPA receptors in maintenance of memory for a passive avoidance task in day-old domestic chicks (Gallus domesticus). Eur. J. Neurosci. 7:1995;1297-1304.
33. Sturgeon R. D., Fessler R. G., Meltzer H. Y. Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotyped behavior and ataxia in rats. Eur. J. Pharmacol. 59:1979;169-179.
34. Turski L., Jacobsen P., Honoré T., Stephens, D. N Relief of experimental spasticity and anxiolytic/anticonvulsant actions of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate antagonist 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F) quinoxaline. J. Pharmacol. Exp. Ther. 260:1992;742-747.
35. Von Euler M., Seiger A., Holmberg L., Sundström E. NBQX, a competitive nonNMDA receptor antagonist, reduces degeneration due to focal spinal cord ischemia. Exp. Neurol. 129:1994;163-168.
36. Wrathall J. R., Choiniere D., Teng Y. D. Dose-dependent reduction of tissue loss and functional impairment after spinal cord trauma with the AMPA/kainate antagonist NBQX. J. Neurosci. 14:1994;6598-6607.
37. Young D., Dragunow M. MK-801 and NBQX prevent electrically induced status epilepticus. Neuroreport. 5:1994;1481-1484.
38. Young D., Dragunow M. Non-NMDA glutamate receptors are involved in the maintenance of status epilepticus. Neuroreport. 5:1993;81-83.
39. Yu W., Miller R. F. NBQX suppresses inhibitory glycine currents in retinal ganglion cells. Neuroreport. 5:1994;1558-1560.
40. Zadow B., Schmidt W. J. The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy. Arch. Pharmacol. 349:1994;61-65.